BSX vs. DXCM, RMD, WST, BMY, CI, REGN, VRTX, MDT, GSK, and HCA
Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include DexCom (DXCM), ResMed (RMD), West Pharmaceutical Services (WST), Bristol-Myers Squibb (BMY), The Cigna Group (CI), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Medtronic (MDT), GSK (GSK), and HCA Healthcare (HCA). These companies are all part of the "medical" sector.
Boston Scientific (NYSE:BSX) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
In the previous week, Boston Scientific had 43 more articles in the media than DexCom. MarketBeat recorded 58 mentions for Boston Scientific and 15 mentions for DexCom. DexCom's average media sentiment score of 0.76 beat Boston Scientific's score of 0.48 indicating that DexCom is being referred to more favorably in the news media.
89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Boston Scientific shares are held by insiders. Comparatively, 0.4% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
DexCom has a net margin of 14.95% compared to Boston Scientific's net margin of 11.19%. DexCom's return on equity of 28.31% beat Boston Scientific's return on equity.
Boston Scientific presently has a consensus target price of $72.73, suggesting a potential downside of 0.75%. DexCom has a consensus target price of $141.40, suggesting a potential upside of 3.63%. Given DexCom's higher probable upside, analysts clearly believe DexCom is more favorable than Boston Scientific.
Boston Scientific has higher revenue and earnings than DexCom. Boston Scientific is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Boston Scientific has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Boston Scientific received 48 more outperform votes than DexCom when rated by MarketBeat users. However, 71.94% of users gave DexCom an outperform vote while only 69.27% of users gave Boston Scientific an outperform vote.
Summary
DexCom beats Boston Scientific on 11 of the 18 factors compared between the two stocks.
Get Boston Scientific News Delivered to You Automatically
Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Boston Scientific Competitors List
Related Companies and Tools
